肿瘤学联合研究与许可协议：2019-2024

本报告调查了肿瘤学领域的联合研究和授权交易，并提供了自2019年以来的合约趋势、肿瘤学领域的联合研究和授权交易、基准分析-交易的市场价值、财务条款、主要交易金额、最活跃交易者等彙整资料。

目录

执行摘要

第1章 - 简介

第2章 肿瘤学交易趋势

• 简介
• 肿瘤学领域合作的长期趋势
• 肿瘤学领域合作，依交易类型
• 肿瘤学领域合作，依产业领域
• 肿瘤学领域合作，依发展阶段
• 肿瘤学领域合作，依技术类型
• 肿瘤学领域合作，依治疗适应症

第3章 - 有关肿瘤学联盟的财务交易条件

• 简介
• 披露的肿瘤学合作的财务条款
• 肿瘤学联盟的头条价值
• 肿瘤学交易预付款
• 肿瘤学交易的里程碑付款
• 肿瘤学交易的特许权使用费率

第4章 - 主要肿瘤学交易与交易人员

• 简介
• 肿瘤学领域最活跃的合作
• 肿瘤学领域最活跃的交易撮合者名单
• 肿瘤学领域的热门交易

第5章 - 癌症现场合约文件目录

• 简介
• 可签约的肿瘤学合作交易

第6章 依治疗标靶划分的癌症领域交易

• 简介
• 依肿瘤治疗目标划分的交易
• 交易目录
• 交易目录 - 肿瘤学交易，依公司划分（2019-2024年）
• 交易目录 - 肿瘤学交易，依技术类型（2019-2024年）
• 交易类型的定义
• 关于Biopharma Research Ltd
• 目前的合作关係
• 当前合约
• Current Partnering的最新报告标题

Oncology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the oncology deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 3,850 oncology deals from 2019 to 2024.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of oncology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in oncology dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the oncology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in oncology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of oncology deals signed and announced since 2019 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of oncology deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in oncology deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Oncology Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse oncology collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Oncology Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of oncology trends and structure of deals entered into by leading biopharma companies worldwide.

Oncology Collaboration and Licensing Deals includes:

• Trends in oncology dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of oncology deal records covering pharmaceutical and biotechnology
• The leading oncology deals by value
• Most active oncology licensing dealmakers

In Oncology Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Oncology Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in oncology dealmaking

• 2.1. Introduction
• 2.2. Oncology partnering over the years
• 2.3. Oncology partnering by deal type
• 2.4. Oncology partnering by industry sector
• 2.5. Oncology partnering by stage of development
• 2.6. Oncology partnering by technology type
• 2.7. Oncology partnering by therapeutic indication

Chapter 3 - Financial deal terms for oncology partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for oncology partnering
• 3.3. Oncology partnering headline values
• 3.4. Oncology deal upfront payments
• 3.5. Oncology deal milestone payments
• 3.6. Oncology royalty rates

Chapter 4 - Leading oncology deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in oncology partnering
• 4.3. List of most active dealmakers in oncology
• 4.4. Top oncology deals by value

Chapter 5 - Oncology contract document directory

• 5.1. Introduction
• 5.2. Oncology partnering deals where contract document available

Chapter 6 - Oncology dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by oncology therapeutic target
• Deal directory
• Deal directory - Oncology deals by company A-Z 2019 to 2024
• Deal directory - Oncology deals by technology type 2019 to 2024
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Oncology partnering since 2019
• Figure 2: Oncology partnering by deal type since 2019
• Figure 3: Oncology partnering by industry sector since 2019
• Figure 4: Oncology partnering by stage of development since 2019
• Figure 5: Oncology partnering by technology type since 2019
• Figure 6: Oncology partnering by indication since 2019
• Figure 7: Oncology deals with a headline value
• Figure 8: Oncology deals with upfront payment values
• Figure 9: Oncology deals with milestone payment
• Figure 10: Oncology deals with royalty rates
• Figure 11: Active oncology dealmaking activity since 2019
• Figure 12: Top oncology deals by value since 2019